Revolution Medicines (RVMD) News Today → Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (From Banyan Hill Publishing) (Ad) Free RVMD Stock Alerts $39.39 +2.01 (+5.38%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 6:29 AM | marketbeat.comEquities Analysts Set Expectations for Revolution Medicines, Inc.'s Q2 2024 Earnings (NASDAQ:RVMD)Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Analysts at HC Wainwright boosted their Q2 2024 EPS estimates for Revolution Medicines in a report released on Monday, May 13th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.73) per share for the quaMay 15 at 5:26 AM | americanbankingnews.comHC Wainwright Comments on Revolution Medicines, Inc.'s Q1 2025 Earnings (NASDAQ:RVMD)May 15 at 4:10 AM | americanbankingnews.comRevolution Medicines' (RVMD) "Buy" Rating Reaffirmed at HC WainwrightMay 14 at 8:25 AM | marketbeat.comAnalysts Issue Forecasts for Revolution Medicines, Inc.'s Q1 2025 Earnings (NASDAQ:RVMD)Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Revolution Medicines in a report issued on Monday, May 13th. HC Wainwright analyst R. Burns expects that the company will post earninMay 13 at 8:19 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $44.00 target price on shares of Revolution Medicines in a research note on Monday.May 13 at 3:57 AM | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Given New $46.00 Price Target at WedbushMay 13 at 2:50 AM | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)May 13 at 1:50 AM | americanbankingnews.comRevolution Medicines, Inc. Forecasted to Post Q2 2024 Earnings of ($0.76) Per Share (NASDAQ:RVMD)May 13 at 1:50 AM | americanbankingnews.comBrokers Issue Forecasts for Revolution Medicines, Inc.'s Q2 2024 Earnings (NASDAQ:RVMD)May 12 at 1:16 AM | americanbankingnews.comAnalyzing Revolution Medicines (NASDAQ:RVMD) and Precision BioSciences (NASDAQ:DTIL)May 11, 2024 | marketbeat.comVictory Capital Management Inc. Has $16.01 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)Victory Capital Management Inc. grew its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 63.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 558,369 shares of the company's stMay 10, 2024 | finance.yahoo.comRevolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...May 10, 2024 | finance.yahoo.comRevolution Medicines First Quarter 2024 Earnings: US$0.70 loss per share (vs US$0.72 loss in 1Q 2023)May 9, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Announces Quarterly Earnings ResultsRevolution Medicines (NASDAQ:RVMD - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.05. The company's revenue was down 100.0% compared to the same quarter last year. During the same period last year, the business posted ($0.72) earnings per share.May 9, 2024 | marketbeat.comWedbush Boosts Revolution Medicines (NASDAQ:RVMD) Price Target to $46.00Wedbush increased their price objective on shares of Revolution Medicines from $42.00 to $46.00 and gave the stock an "outperform" rating in a research report on Thursday.May 9, 2024 | finance.yahoo.comRevolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 9, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $46.00 price objective on shares of Revolution Medicines in a report on Thursday.May 8, 2024 | msn.comRVMD Stock Earnings: Revolution Medicines Beats EPS for Q1 2024May 8, 2024 | globenewswire.comRevolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate ProgressMay 7, 2024 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Trading Down 4.2% on Insider SellingMay 6, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Down 4.2% on Insider SellingRevolution Medicines (NASDAQ:RVMD) Stock Price Down 4.2% Following Insider SellingMay 5, 2024 | insidertrades.comJack Anders Sells 10,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockMay 4, 2024 | finance.yahoo.comInsider Sale: CFO Jack Anders Sells 10,000 Shares of Revolution Medicines Inc (RVMD)May 3, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) CFO Sells $400,300.00 in StockRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $40.03, for a total transaction of $400,300.00. Following the transaction, the chief financial officer now directly owns 101,959 shares in the company, valued at $4,081,418.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.May 2, 2024 | marketbeat.comRevolution Medicines (RVMD) to Release Earnings on WednesdayRevolution Medicines (NASDAQ:RVMD) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Reaches New 1-Year High at $39.00Revolution Medicines (NASDAQ:RVMD) Hits New 1-Year High at $39.00May 1, 2024 | globenewswire.comRevolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024April 29, 2024 | marketbeat.comHandelsbanken Fonder AB Acquires 25,975 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Handelsbanken Fonder AB raised its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 182.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,175 shares of the company's stock after purcApril 27, 2024 | marketbeat.comState of New Jersey Common Pension Fund D Purchases 38,363 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)State of New Jersey Common Pension Fund D lifted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 51.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 113,390 shares of the companyApril 27, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by AnalystsRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) has earned a consensus rating of "Buy" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the cApril 20, 2024 | marketbeat.comSG Americas Securities LLC Trims Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)SG Americas Securities LLC lowered its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 93.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,595 shares of the company's stock after selling 54,206 shares during the pApril 19, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Mirae Asset Global Investments Co. Ltd.Mirae Asset Global Investments Co. Ltd. increased its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 45.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 80,405 shares of the compApril 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - RVMDApril 17, 2024 | msn.comRevolution Medicines (RVMD) Price Target Increased by 5.15% to 41.65April 15, 2024 | investing.comRevolution Medicines executive sells over $619k in company stockApril 14, 2024 | investing.comRevolution Medicines director sells shares worth $79,735April 13, 2024 | insidertrades.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 2,155 Shares of StockApril 12, 2024 | marketbeat.comInsider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 7,500 Shares of StockRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark A. Goldsmith sold 7,500 shares of Revolution Medicines stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $35.48, for a total value of $266,100.00. Following the completion of the transaction, the insider now owns 452,879 shares in the company, valued at $16,068,146.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.April 12, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Short Interest Down 26.8% in MarchRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) saw a large decline in short interest in March. As of March 31st, there was short interest totalling 12,000,000 shares, a decline of 26.8% from the March 15th total of 16,400,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is currently 8.9 days.April 12, 2024 | markets.businessinsider.comBuy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer TherapiesApril 12, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) PT Raised to $45.00 at OppenheimerOppenheimer upped their price target on Revolution Medicines from $43.00 to $45.00 and gave the company an "outperform" rating in a report on Friday.April 11, 2024 | uk.investing.comRevolution Medicines reports progress in RAS cancer therapyApril 11, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Reaches New 52-Week High at $37.62Revolution Medicines (NASDAQ:RVMD) Reaches New 12-Month High at $37.62April 10, 2024 | msn.comWhat's Going On With Revolution Medicines Stock?April 10, 2024 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Upgraded to "Strong-Buy" at Raymond JamesRaymond James upgraded shares of Revolution Medicines from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the stock from $36.00 to $48.00 in a research note on Wednesday.April 10, 2024 | uk.investing.comRevolution Medicines reports breakthrough in RAS-mutant cancer treatmentApril 9, 2024 | globenewswire.comRevolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsApril 8, 2024 | markets.businessinsider.comRevolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy RatingApril 8, 2024 | globenewswire.comRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsApril 4, 2024 | globenewswire.comRevolution Medicines to Participate in Upcoming Investor Conferences Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address He cracked the code to crypto… (Ad)Juan Villaverde has cracked the code to crypto. Click now for the best way into the newest AI projects RVMD Media Mentions By Week RVMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVMD News Sentiment▼0.590.55▲Average Medical News Sentiment RVMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVMD Articles This Week▼314▲RVMD Articles Average Week Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EXEL News PCVX News IBRX News HALO News CRSP News KRYS News IMVT News MRTX News IOVA News RGEN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVMD) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDoes this make you sick?Allegiance GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
